Skip to main content

MINI REVIEW article

Front. Pharmacol.
Sec. Pharmacology of Anti-Cancer Drugs
Volume 15 - 2024 | doi: 10.3389/fphar.2024.1485919
This article is part of the Research Topic Innovative Approaches in Glioma Therapy: Exploring New Therapeutic Frontiers View all articles

Fyn, an important molecule in the brain, is a potential therapeutic target for brain tumours

Provisionally accepted
Ruiqi Chen Ruiqi Chen 1*Chongxi Xu Chongxi Xu 1Yi Tang Yi Tang 2Xing Lu Xing Lu 3
  • 1 West China School of Medicine, West China Hospital, Sichuan University, Chengdu, China
  • 2 Sichuan Cancer Hospital, Chengdu, Sichuan Province, China
  • 3 West China Second University Hospital, Sichuan University, Chengdu, Sichuan Province, China

The final, formatted version of the article will be published soon.

    Under normal physiological conditions, Fyn, a nonreceptor tyrosine kinase, is involved in signal transduction pathways in the nervous system and in the formation and activation of T lymphocytes. Fyn is a member of the Src family of kinases (SFKs) and plays a role in cell morphogenic transformation, motility, proliferation, and death, which in turn influences the development and progression of various cancer types. SFKs are overexpressed or hyperactive in tumours, and they are engaged in several signalling pathways that lead to tumour development. Inhibition of Fyn can enhance patient outcomes and prolong survival. Thus, Fyn is a desirable therapeutic target in a variety of tumour types. To lay the groundwork for further investigation and targeted therapy in tumours, in this article, we review the most recent findings on the function of Fyn in tumours, with an emphasis on its role in gliomas. Understanding the function of Fyn during tumourigenesis and development and in resistance to anticancer therapeutic agents can aid in the development and application of innovative medicines that specifically target this kinase, thus improving the management of cancers.

    Keywords: Fyn, brain tumours, Src family of kinases, gliomas, Therapeutic target

    Received: 25 Aug 2024; Accepted: 22 Nov 2024.

    Copyright: © 2024 Chen, Xu, Tang and Lu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence: Ruiqi Chen, West China School of Medicine, West China Hospital, Sichuan University, Chengdu, China

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.